Neven P, Fasching PA, Chia S, Jerusalem G, et al. Updated overall survival from the MONALEESA-3 trial in postmenopausal women with HR+/HER2- advanced breast cancer receiving first-line ribociclib plus fulvestrant. Breast Cancer Res 2023;25:103.
PMID: 37653397